Tagrisso is only first-line treatment for EGFR-mutated NSCLC to deliver median overall survival of over three years

Image: Tagrisso showed a statistically significant and clinically meaningful 52% reduction in the risk of central nervous system disease progression. Photo: courtesy of AstraZeneca.